Search

Your search keyword '"Han, Jungmi"' showing total 5 results
Start Over Author "Han, Jungmi" Topic messenger rna
5 results on '"Han, Jungmi"'

1. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance--VISION Network, 10 States, December 2021-August 2022

Author

Britton, Amadea, Embi, Peter J., Levy, Matthew E., Gaglani, Manjusha, DeSilva, Malini B., Dixon, Brian E., Dascomb, Kristin, Patel, Palak, Schrader, Kristin E., Klein, Nicola P., Ong, Toan C., Natarajan, Karthik, Hartmann, Emily, Kharbanda, Anupam B., Irving, Stephanie A., Dickerson, Monica, Dunne, Margaret M., Raiyani, Chandni, Grannis, Shaun J., Stenehjem, Edward, Zerbo, Ousseny, Rao, Suchitra, Han, Jungmi, Sloan-Aagard, Chantel, Griggs, Eric P., Weber, Zachary A., Murthy, Kempapura, Fadel, William F., Grisel, Nancy, McEvoy, Charlene, Lewis, Ned, Barron, Michelle A., Nanez, Juan, Reese, Sarah E., Mamawala, Mufaddal, Valvi, Nimish R., Arndorfer, Julie, Goddard, Kristin, Yang, Duck- Hye, Fireman, Bruce, Ball, Sarah W., Link-Gelles, Ruth, Naleway, Allison L., and Tenforde, Mark W.

Subjects
Diseases, Vaccines, Vaccination, COVID-19, Messenger RNA, Adults
Abstract

Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared with persons without immunocompromising conditions (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) [...]

Published
2022

2. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated--VISION Network, 10 States, December 2021-June 2022

Author

Link-Gelles, Ruth, Levy, Matthew E., Gaglani, Manjusha, Irving, Stephanie A., Stockwell, Melissa, Dascomb, Kristin, DeSilva, Malini B., Reese, Sarah E., Liao, I-Chia, Ong, Toan C., Grannis, Shaun J., McEvoy, Charlene, Patel, Palak, Klein, Nicola P., Hartmann, Emily, Stenehjem, Edward, Natarajan, Karthik, Naleway, Allison L., Murthy, Kempapura, Rao, Suchitra, Dixon, Brian E., Kharbanda, Anupam B., Akinseye, Akintunde, Dickerson, Monica, Lewis, Ned, Grisel, Nancy, Han, Jungmi, Barron, Michelle A., Fadel, William F., Dunne, Margaret M., Goddard, Kristin, Arndorfer, Julie, Konatham, Deepika, Valvi, Nimish R., Currey, J.C., Fireman, Bruce, Raiyani, Chandni, Zerbo, Ousseny, Sloan-Aagard, Chantel, Ball, Sarah W., Thompson, Mark G., and Tenforde, Mark W.

Subjects
University of Colorado, Diseases, Vaccines, Medical research, Infection, COVID-19, Messenger RNA, Adults, Medicine, Experimental
Abstract

On July 15, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was [...]

Published
2022

3. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance--VISION Network, 10 States, August 2021-January 2022

Author

Ferdinands, Jill M., Rao, Suchitra, Dixon, Brian E., Mitchell, Patrick K., DeSilva, Malini B., Irving, Stephanie A., Lewis, Ned, Natarajan, Karthik, Stenehjem, Edward, Grannis, Shaun J., Han, Jungmi, McEvoy, Charlene, Ong, Toan C., Naleway, Allison L., Reese, Sarah E., Embi, Peter J., Dascomb, Kristin, Klein, Nicola P., Griggs, Eric P., Konatham, Deepika, Kharbanda, Anupam B., Yang, Duck-Hye, Fadel, William F., Grisel, Nancy, Goddard, Kristin, Patel, Palak, Liao, I-Chia, Birch, Rebecca, Valvi, Nimish R., Reynolds, Sue, Arndorfer, Julie, Zerbo, Ousseny, Murthy, Monica Dickerson Kempapura, Williams, Jeremiah, Bozio, Catherine H., Blanton, Lenee, Verani, Jennifer R., Schrag, Stephanie J., Dalton, Alexandra F., Wondimu, Mehiret H., Link-Gelles, Ruth, Azziz-Baumgartner, Eduardo, Barron, Michelle A., Gaglani, Manjusha, Thompson, Mark G., and Fireman, Bruce

Subjects
Pfizer Inc., Diseases, Vaccines, Hospital emergency services, Vaccination, Emergency medicine, Pharmaceutical industry, COVID-19, Messenger RNA, Adults, Hospitals -- Emergency service
Abstract

On February 11, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). CDC recommends that all persons aged [greater than or equal to] 12 [...]

Published
2022

4. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19--Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance--VISION Network, 10 States, August 2021-January 2022

Author

Thompson, Mark G., Natarajan, Karthik, Irving, Stephanie A., Rowley, Elizabeth A., Griggs, Eric P., Gaglani, Manjusha, Klein, Nicola P., Grannis, Shaun J., DeSilva, Malini B., Stenehjem, Edward, Reese, Sarah E., Dickerson, Monica, Naleway, Allison L., Han, Jungmi, Konatham, Deepika, McEvoy, Charlene, Rao, Suchitra, Dixon, Brian E., Dascomb, Kristin, Lewis, Ned, Levy, Matthew E., Patel, Palak, Liao, I-Chia, Kharbanda, Anupam B., Barron, Michelle A., Fadel, William F., Grisel, Nancy, Goddard, Kristin, Yang, Duck-Hye, Wondimu, Mehiret H., Murthy, Kempapura, Valvi, Nimish R., Arndorfer, Julie, Fireman, Bruce, Dunne, Margaret M., Embi, Peter, Azziz-Baumgartner, Eduardo, Zerbo, Ousseny, Bozio, Catherine H., Reynolds, Sue, Ferdinands, Jill, Williams, Jeremiah, Link-Gelles, Ruth, Schrag, Stephanie J., Verani, Jennifer R., Ball, Sarah, and Ong, Toan C.

Subjects
Pfizer Inc., University of Colorado, Comirnaty (Vaccine), Diseases, Vaccines, Hospital emergency services, Medical research, Emergency medicine, Pharmaceutical industry, COVID-19, Messenger RNA, Adults, Medicine, Experimental, Hospitals -- Emergency service
Abstract

On January 21, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months [...]

Published
2022

5. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults--Nine States, January-September 2021

Author

Embi, Peter J., Levy, Matthew E., Naleway, Allison L., Patel, Palak, Gaglani, Manjusha, Natarajan, Karthik, Dascomb, Kristin, Ong, Toan C., Klein, Nicola P., Liao, I.-Chia, Grannis, Shaun J., Han, Jungmi, Stenehjem, Edward, Dunne, Margaret M., Lewis, Ned, Irving, Stephanie A., Rao, Suchitra, McEvoy, Charlene, Bozio, Catherine H., Murthy, Kempapura, Dixon, Brian E., Grisel, Nancy, Yang, Duck-Hye, Goddard, Kristin, Kharbanda, Anupam B., Reynolds, Sue, Raiyani, Chandni, Fadel, William F., Arndorfer, Julie, Rowley, Elizabeth A., Fireman, Bruce, Ferdinands, Jill, Valvi, Nimish R., Ball, Sarah W., Zerbo, Ousseny, Griggs, Eric P., Mitchell, Patrick K., Porter, Rachael M., Kiduko, Salome A., Blanton, Lenee, Zhuang, Yan, Steffens, Andrea, Reese, Sarah E., Olson, Natalie, Williams, Jeremiah, Dickerson, Monica, McMorrow, Meredith, Schrag, Stephanie J., Verani, Jennifer R., Fry, Alicia M., Azziz-Baumgartner, Eduardo, Barron, Michelle A., Thompson, Mark G., and DeSilva, Malini B.

Subjects
Pfizer Inc., Vaccination, Pharmaceutical industry, COVID-19, Messenger RNA, Adults
Abstract

On November 2, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Immunocompromised persons, defined as those with suppressed humoral or cellular immunity resulting [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results